Business Wire

STALICLA Awarded EUR 1.7 Million to Lead Computational Drug Repositioning Activities in EU-funded REPO4EU Project

Share

REPO4EU consortium seeks to address the urgent need for new cost-effective therapies, as well as to improve existing treatments through international cooperation, pooling research and innovation expertise. A total of EUR 22 million grant has been awarded to REPO4EU by EU (HORIZON-HLTH-DISEASE-2021-04-02) within the Key Strategic Orientation KSO-D ‘Creating a more resilient, inclusive and democratic European society’ of Horizon Europe’s Strategic Plan 2021-2024. REPO4EU is one of the only two projects retained among 13 full consortium applications. STALICLA DDS was granted a EUR 1.7 million budget over 6 years to act as leader for in silico drug repositioning work tasks. STALICLA DDS will bring its technology and know-how to analyze biosample and clinical data from hundreds of patients with neurodevelopmental disorders (NDDs).

Lynn DURHAM, STALICLA’s CEO stated that “STALICLA is thrilled to be leading the REPO4EU in silico drug repositioning work task project. This achievement is a strong acknowledgement of STALICLA’s technology and expertise in accelerating precision medicine discovery for patients with complex diseases.”

It takes on average 15 years for promising drug candidates to reach the market. Repositioning investigational medicinal products beyond their original pursued indication is an efficient strategy to reduce timelines, costs and attrition in drug development. STALICLA will contribute to REPO4EU its unique know-how of in silico systems biology and artificial intelligence applications for patient stratification and treatment identification.

For more information see:

REPO4EU consortium web https://repo4.eu/ and twitter https://twitter.com/REPO4EU

The funding call https://cordis.europa.eu/programme/id/HORIZON_HORIZON-HLTH-2021-DISEASE-04-02 and info on the resolution of the call https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-hlth-2021-disease-04-02

About STALICLA

STALICLA is a clinical stage biotech company advancing the first clinically validated precision medicine platform for patients with Neurodevelopmental Disorders (NDDs), with a first application in Autism Spectrum Disorder (ASD).

STALICLA has already identified and validated clinically and biologically several subgroups of patients with ASD and corresponding treatment candidates.

STP1, STALICLA’s first lead treatment, aims to serve a first biological subgroup of patients with ASD- ASD-Phenotype 1.

STP1 has successfully completed clinical Phase 1b in early 2022, showing good safety/tolerability, positive target engagement, and superiority in cognition endpoints in treatment versus placebo groups. In 2023, STP1 will enter Phase 2; STP2, a phase 2 ready compound tailored for the treatment of ASD-Phenotype 2 patients will also be entering Phase 2. For more information, please visit: https://stalicla.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

info@stalicla.com
+41 22 545 12 42

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mercans Welcomes Global Payroll Thought Leader Pete Tiliakos to Its Board7.2.2023 15:43:00 CET | Press release

Mercans, the global payroll technology leader, announced today that Pete Tiliakos has joined its board as a non-executive director. Pete is a renowned global payroll product strategy leader, HR industry analyst, advisor, and thought leader. This appointment follows industry veteran Steve Goldberg joining Mercans’ board last October. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005824/en/ Pete Tiliakos (Photo: AETOSWire) When announcing Pete’s appointment, Mercans’ board said, “Pete brings an independent and fresh perspective to Mercans’ strategy and governance structure. His experience and insights strengthen the board and executive management team of the global payroll and EOR service provider. Pete’s extensive industry knowledge is highly sought after and his perspectives are highly regarded. We are excited to have Pete join Mercans’ board and look forward to working with him on strengthening Mercans’ leadership in

Dexcom and Nick Jonas Make Super Bowl Magic to Launch New Dexcom G7 Continuous Glucose Monitoring System7.2.2023 15:25:00 CET | Press release

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today unveiled the company’s second Super Bowl commercial, which announces the US launch of its next-generation Dexcom G7 CGM System. The ad, which will run during the second quarter of Super Bowl LVII on Feb. 12, 2023, stars multi-platinum recording artist, songwriter, actor and philanthropist, Nick Jonas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005121/en/ Nick Jonas on set during production of Dexcom's 2023 Super Bowl commercial launching its new Dexcom G7 CGM System. (Photo: Business Wire) “Dexcom CGM has changed my life and revolutionized the way I take care of my health,” said Jonas. “People with diabetes – whether Type 1 or Type 2 – should have the best technology available to manage their disease, and with Dexcom G7, they’ll have it. I’m excited for the opportunity to share this new device wi

Globe Union Gains Competitive Momentum by Moving to Rimini Street, Improving ERP Maintenance ROI and Optimizing Talent Resources7.2.2023 15:01:00 CET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products, and a Salesforce partner, today announced that Globe Union, a market leader in kitchen and bath products, has selected Rimini Street to effectively resolve quality, cost, and talent shortage challenges caused by waning vendor software support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005053/en/ Globe Union accelerates key innovation projects, reallocates labor and time, and saves hard costs by choosing Rimini Street's Smart Path. (Photo: Business Wire) Globe Union champions the concept of end-to-end quality assurance, starting with expert raw material processing, to experiential consumer packaging. With highest standards as its guiding principle, the company reviewed and took action against the increasing cost for maintaining its Oracle

Avania Acquires MAXIS, Advancing MedTech Leadership in Pre-Clinical, Regulatory Strategy, and Clinical Expertise7.2.2023 15:00:00 CET | Press release

Avania, a leading, global medical technology contract research organization (CRO), today announced its acquisition of MAXIS, a prominent medical technology development service provider with expertise in pre-clinical engineering, design validation and verification, regulatory affairs, field clinical services, and trial management. MAXIS has offices in San Jose, California, and Frankfurt am Main, Germany, with additional operational staff across the regions. With MAXIS, the combined organization offers unmatched high-touch strategic and operational expertise that uniquely drive results for medical device innovators and emerging original equipment manufacturers (OEMs). “This acquisition strengthens our position as the leading MedTech focused CRO, advancing innovative medical technologies from ideation to commercialization, providing a range of highly customizable services in combination with robust global regulatory, clinical, and operational strategies to meet the unique needs of emergin

AlertEnterprise Reveals New Guardian Platform Integration With Nedap AEOS Access Control System7.2.2023 15:00:00 CET | Press release

AlertEnterprise, Inc., the leading cyber-physical security convergence software company, today announced a new integration with Nedap AEOS access control platform. This cyber-physical integration connects Nedap AEOS with AlertEnterprise Guardian AI-powered physical identity access management (PIAM) cloud platform for automated, secure and compliant workplace access. Say goodbye to clunky, outdated manual approaches to access control. With this integration, businesses of all sizes can finally bridge the gap between IT security controls and physical security measures, all while leveraging AI to streamline the process of managing user identities and building access. As Yogesh Ailawadi, AlertEnterprise SVP of Product Management and Solution Engineering puts it, "In the new reality of the hybrid workplace, organizations are wasting valuable resources and increasing risk with outdated manual approaches to access control. By interfacing AlertEnterprise Guardian with Nedap AEOS, companies can

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom